Hi doctor, thanks for your recommendation. I have decided after some research as well as based on yo

                danmark danmark  
Hi doctor, thanks for your recommendation. I have decided after some research as well as based on your recommendation that I would start the treatment. danmark My next visit in early May would be to review my genotype results and decide on the drug to use. To recap, my viral load during acute stage was 2 million copies and cd4 at 295 counts. danmark Here are a couple of questions I wish you could advise to help me on making the right decision: 1. Assuming no preexisting danmark resistance, is there specific drugs recommended? 2. I understand atripla is currently the standard danmark recommended drug but complera and striblid are good options too. As my major concern is the long term toxicity, danmark may I understand danmark which drug is known to be more tolerated? 3. Are all once daily pill have the same effect of lipostrophy? If not, which has the best chance to avoid it? 4. My social worker informed me the standard combination danmark being used nowadays are epivir sustiva and Viread . Do they work similarly as atripla? 5. Do all the once daily pills have the same ability to cross the blood brain barrier, and if I pick the ones that do, would I have better chance to avoid hiv related brain damage? 6. Do you think by taking supplements and the right food, I would be able to reduce danmark the side effects eg heart diseases and diabetes?
There are a lot of factors which go into choosing a first line regimen. Current US treatment guidelines recommend (or call "preferred") seven different regimens- 1 using a NNRTI ( efavirenz ), 2 with boosted PIs ( atazanavir or darunavir ) and 4 with integrase inhibitors. The US Department of Health and Human Services recently updated their guidelines to include 4 integrase regimens.
In my opinion, the days of general use of first-line NNRTIs and PIs in the US are waning and integrase inhibitors ( raltegravir , elvitegravir and dolutegravir ) should not be the basis for all preferred first-line danmark treatments. This is because of a number of studies which have shown significantly better tolerability and statistical superiority of the integrase inhibitors over efavirenz (2 studies) and PIs (2 studies). None of the newer regimens danmark are particularly danmark associated with increasing risk of lipodystrophy ; I haven't started a new patient on Atripla for many years because of efavirenz-related side effects.
I'd recommen